Neuroinflammation in heart failure: NEW insights for an old disease

Hugo S. Díaz,Camilo Toledo,David C. Andrade,Noah J. Marcus,Rodrigo Del Rio

DOI: https://doi.org/10.1113/JP278864

2019-11-02

Journal of Physiology

Abstract:Heart failure (HF) is a complex clinical syndrome affecting roughly 26 million people worldwide. Increased sympathetic drive is a hallmark of HF and is associated with disease progression and higher mortality risk. Several mechanisms contribute to enhanced sympathetic activity in HF, however these pathways are still incompletely understood. Previous work suggests that inflammation and activation of the renin‐angiotensin system (RAS) increases sympathetic drive. Importantly, chronic inflammation in several brain regions is commonly observed in aged populations, and a growing body of evidence suggests neuroinflammation plays a crucial role in HF. In animal models of HF, central inhibition of RAS and pro‐inflammatory cytokines normalizes sympathetic drive and improves cardiac function. The precise molecular and cellular mechanisms that lead to neuroinflammation and its effect on HF progression remain undetermined. This review will summarize the most recent advances in the field of neuroinflammation and autonomic control in HF. In addition, we will focus on cellular and molecular mediators of neuroinflammation in HF with a focus on brain regions involved in sympathetic control. Finally, we will comment on what is known about neuroinflammation in the context of preserved vs. reduced ejection fraction HF. Integrative physiology of heart failure progression : Heart failure (HF) is characterized by chronic inflammation, Renin‐Angiotensin system (RAS) overactivity, sympathoexcitation, and cardiac dysfunction. Sympathoexcitation and RAS activation occur early in HF progression as a compensatory response to hemodynamic challenges. Chronic activation of these compensatory mechanisms becomes maladaptive and has toxic effects on cardiac muscle leading to electrophysiological abnormalities and initiation of fibrotic processes. RAS activation also enhances chemoreflex sensitivity (further exacerbating sympathetic activation) and promotes diffuse inflammation. Both systemic and brain RAS and inflammation feeds back to exacerbate sympathoexcitation, generating a vicious cycle that contributes to further cardiac dysfunction.2 This article is protected by copyright. All rights reserved